Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00376948|
Recruitment Status : Completed
First Posted : September 15, 2006
Results First Posted : August 26, 2014
Last Update Posted : December 4, 2017
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genistein may help gemcitabine and erlotinib kill more tumor cells by making tumor cells more sensitive to the drugs.
PURPOSE: This phase II trial is studying how well giving genistein together with gemcitabine and erlotinib works in treating patients with locally advanced or metastatic pancreatic cancer.
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Cancer||Dietary Supplement: genistein Drug: erlotinib hydrochloride Drug: gemcitabine hydrochloride||Phase 2|
- Determine the 6-month survival rate of patients with locally advanced or metastatic pancreatic cancer treated with genistein, gemcitabine hydrochloride, and erlotinib hydrochloride.
- Determine the frequency of objective tumor response rate in these patients.
- Determine the time to treatment failure in these patients.
- Determine the effect of baseline expression of pAKT and activation of NF-kappaB on survival of patients treated with this regimen.
- Determine the overall time to disease progression in these patients.
- Estimate the quantitative and qualitative toxicities of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral genistein twice daily on days -7 to 28 in course 1 and on days 1-28 in all other courses. Patients also receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and oral erlotinib hydrochloride once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Trial of Novasoy®, Gemcitabine, and Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer|
|Study Start Date :||May 2005|
|Actual Primary Completion Date :||March 2010|
|Actual Study Completion Date :||March 2010|
Experimental: Novasoy®, Gemcitabine & Erlotinib
Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, & 15; Erlotinib 150 mg day 1 until day 28
Dietary Supplement: genistein
Drug: erlotinib hydrochloride
Drug: gemcitabine hydrochloride
- Patients Alive [ Time Frame: at 6 months ]
- Median Overall Survival Estimate [ Time Frame: up to 17 months ]
- Overall Objective Response Rate (Complete and Partial Response) [ Time Frame: Every 8 weeks ]Imaging tests (CT scan, CXR [Chest X-Ray], MRI or imaging studies as clinically indicated
- Response Duration, Time to Treatment Failure, and Time to Progression [ Time Frame: Every 8 weeks ]Imaging tests (CT scan, CXR, MRI or imaging studies as clinically indicated
- Toxicity [ Time Frame: First day of each cycle ]Toxicity evaluation using NCI-CTC (Common Terminology Criteria) v.3 criteria; CBC (complete blood count) with differential white cell and platelet counts; Serum sodium, potassium, chloride, bicarbonate, AST, ALT, alkaline phosphatase, total bilirubin, blood urea nitrogen, creatinine, and albumin; Serum CA 19-9
- pAKT (Pichia Anomala Killer Toxin) and NF (Nuclear Factor)-kappaB Activation [ Time Frame: At start of study ]Tumor tissue collected from paraffin
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00376948
|United States, Michigan|
|Barbara Ann Karmanos Cancer Institute|
|Detroit, Michigan, United States, 48201-1379|
|United States, Texas|
|M. D. Anderson Cancer Center at University of Texas|
|Houston, Texas, United States, 77030-4009|
|Principal Investigator:||Khaldoun Almhanna, MD||Barbara Ann Karmanos Cancer Institute|
|Principal Investigator:||Fazlul H. Sarkar, PhD||Barbara Ann Karmanos Cancer Institute|